KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Acadia Pharmaceuticals (ACAD) over the last 13 years, with Q3 2025 value amounting to $23.6 million.

  • Acadia Pharmaceuticals' Receivables - Other rose 9407.6% to $23.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.6 million, marking a year-over-year increase of 9407.6%. This contributed to the annual value of $6.0 million for FY2024, which is 4587.31% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Receivables - Other stood at $23.6 million for Q3 2025, which was up 9407.6% from $12.2 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Receivables - Other peaked at $23.6 million during Q3 2025, and registered a low of $403000.0 during Q3 2022.
  • Moreover, its 5-year median value for Receivables - Other was $2.3 million (2023), whereas its average is $4.9 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first tumbled by 8098.81% in 2021, then skyrocketed by 60254.34% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Receivables - Other (Quarter) stood at $978000.0 in 2021, then fell by 9.51% to $885000.0 in 2022, then soared by 361.36% to $4.1 million in 2023, then soared by 45.87% to $6.0 million in 2024, then surged by 296.04% to $23.6 million in 2025.
  • Its Receivables - Other stands at $23.6 million for Q3 2025, versus $12.2 million for Q2 2025 and $8.0 million for Q1 2025.